Evaluation of changes in rat fatigability and biochemical parameters after oral and intra-peritoneal administration of adenosine tri phosphate: an experimental study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20164134Keywords:
Adenosine tri phosphate, Hyperuricemia, HyperglycemiaAbstract
Background: Adenosine tri phosphate (ATP) is an important intracellular energy source and has many extracellular functions meadiacating through purine receptors. Currently ATP is available in the market as oral dietary supplement. However there are inconclusive studies regarding its efficacy through oral route. Hence this study was carried out to evaluate efficacy of oral and intraperitoneal administration of ATP in experimental rats by comparing swim exhaust time and associated biochemical changes.
Methods: 18 Swiss albino rats of either gender were grouped randomly into three groups, consisting of group -1 control group which receive distilled water (5ml/kg body weight) whereas group 2 and 3 received oral and intraperitoneal ATP (60mg/kg body weight) for 8 days. On 8th day all rats all rats were evaluated for extent of physical fatigue by using exhaustive swimming test time required to attain immobility status is noted. Under aseptic precautions blood samples were drawn from rat tail vein and biochemical parameters like uric acid, triglycerides, total cholesterol, random blood sugar and c-reactive protein levels were measured.
Results: There was a significant (p<0.05) increase in serum uric acid, blood sugar and urea in Group 2and3 compared control group 1. There was no statistically significant increase in physical strength in group 2 and 3 as compared to group 1.
Conclusions: Oral and intraperitoneal administration of ATP may lead to hyperglycaemia, hyperuricemia and dyslipidaemia without significant increase in muscle strength.
References
Burnstock G. Purinergic signalling. British J Pharmacology. 2006;147(1):172-81.
Kushmerick MJ, Conley KE. Energetics of muscle contraction: The whole is less than the sum of its parts. Biochem Soc Trans. 2002;30(2):227-31.
Agteresch HJ, Dagnelie PC, Van den Berg JW, Wilson JH. Adenosine triphosphate: established and potential clinical applications. Drugs. 1999;58(2):211-32.
Burnstock G, Knight GE, Greig AV.Purinergic signaling in healthy and diseased skin. J Invest Dermatol. 2012;132(3 Pt 1):526-46.
Burnstock G, Ralevic V. Pharmacological reviews. Purinergic Signaling and Blood Vessels in Health and Disease. 2013;66(1):102-92.
Carver JD. Dietary nucleotides: effects on the immune and gastrointestinal systems Issue Acta Paediatrica 1999;88(430):83-8.
Lerner A and Shamir R. Reviews Nucleotides in Infant Nutrition: A Must or an Option IMAJ. 2000;2:772-74.
Bannwarth B, Allaert FA, Avouac B, Rossignol M, Rozenberg S, and Valat JP.A randomized, double-blind, placebo controlled triphosphate in study of oral adenosine subacute low back pain. The Journal of Rheumatology. 2005;32(6):1114-7.
Long G, Zhang GQ. Effects of Adenosine Triphosphate (ATP) on Early Recovery After Total Knee Arthroplasty (TKA): A Randomized, Double-Blind, Controlled Study The Journal of Arthroplasty. 2014;29(12):2347-51.
Zhang L, Liang L, Tong T, Qin Y, Xu Y, Tong X. Antihyperlipidemic activity of adenosine triphosphate in rabbits fed a high-fat diet and hyperlipidemic patients. Pharm Biol. 2016;9:1-6.
Arts ICW, Coolen EJCM, Martijn JL, Bours MJL, Huyghebaert N, Stuart MAC, et al. Adenosine 5′-triphosphate (ATP) supplements are not orally bioavailable: A randomized, placebo-controlled cross-over trial in healthy humans. JISSN. 2012;9:16.
Hendrick JA, Trienet R, Leon GM, J William O. van den Berg, Paul Wilson JH, et al. Beneficial effects of Adenosine Triphosphate on nutritional status in advanced lung cancer patients: A randomized clinical trial. Journal of Clinical Oncology. 2002;20(2):371-8.
Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto-5’- nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest. 2002;110:993-1002.
Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside transporter proteins. Curr Vasc Pharmacol. 2009;7:426-34.
Gorman MW, Feigl EO, Buffington CW. Human plasma ATP concentration. Clin Chem. 2007;53:318-25.
Gorman MW, Feigl EO, Buffington CW. Measurement of adenine nucleotides in plasma. Luminescence. 2003;18(3):173-81.
Ngo LY, Patil SD, Unadkat JD. Ontogenic and longitudinal activity of Na(+)nucleoside transporters in the human intestine. Am J Physiol Gastrointest Liver Physiol. 2001;280:475-81.
Pastor-Anglada M, Errasti-Murugarren E, Aymerich I, Casado FJ. Concentrative nucleoside transporters (CNTs) in epithelia: from absorption to cell signaling. J Physiol Biochem. 2007;63:97-110.
Puig JG, Martínez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008;20(2):187-91.
Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210-6.
Remedios C, Shah M, Bhasker AG, Lakdawala M. Hyperuricemia: a reality in the Indian obese. Obes Surg. 2012;22(6):945-8.
22. Kichenin K, Seman M. Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. J Pharmacol Exp Ther. 2000;294:126-33.
Kichenin K, Decollogne S, Angignard J, Seman M. Cardiovascular and pulmonary response to oral administration of ATP in rabbits. J Appl Physiol. 2000;88:1962-8.
Rathmacher JA, Fuller JC, BaierSM, Abumrad NN, Angus HF, Sharp RL. Adenosine-5'-triphosphate (ATP) supplementation improves low peak muscle torque and torque fatigue during repeated high intensity exercise sets. Journal of the International Society of Sports Nutrition. 2012;9(48):1-7.
Wilson JM, Joy JM, Lowery RP, Roberts MD, Lockwood CM, Manninen AH, et al., Effects of oral adenosine-5'-triphosphate supplementation on athletic performance, skeletal muscle hypertrophy and recovery in resistance-trained men. Nutr Metab. 2013;10(1):57.
Ju J, Hirose S, Shi X, Ishii A, Hu LY, Zou LP. Treatment with Oral ATP decreases alternating hemiplegia of childhood with de novo ATP1A3 Mutation. Orphanet J Rare Dis. 2016;11:55.
Charles BA, Shriner D, Doumatey A, Chen G, Zhou J, Huang H, et al. A genome-wide association study of serum uric acid in African Americans. BMC Med Genomics. 2011;4:17.
Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism. 2008;57:845-52.
Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: A 15-year follow-up study.Am J Epidemiol. 2012;176:108-16.
Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D et.al, Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations Nephron Exp Nephrol. 2012;121:71-8.
Lv Q, Meng X-F, He F-F, Chen S, Su H, Xiong J, et al. High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies. PLoS ONE. 2013;8(2):e56864.
Wakuda H, Uchida S, Ikeda M, Tabuchi M, Akahoshi Y, Shinozuka K,et al. Is Hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice. Biol Pharm Bull. 2014;37(12):1866-71.
Peng T, Wang C,Kao T, Chan JY, Yang Y, Chang Y,et al. Relationship between Hyperuricemia and Lipid Profiles in US Adults. Biomed Res Int. 2015;e127596.
Keenan T, Blaha MJ, Nasir K, Silverman MG, Tota-Maharaj R, Carvalho JA, et al. Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol. 2012;15;110(12):1787-92.
Isha, Jain VK, Lal H. C-Reactive Protein and Uric Acid Levels in Patients with Psoriasis. Indian J Clin Biochem. 2011;26(3):309-11.
Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG. C-reactive protein concentration and risk of coronary heart disease, stroke and mortality: An individual participant meta-analysis. Lancet. 2010;375:132-40.
Zimmermann H. Extracellular purine metabolism. Drug Dev Res. 1996;39:337-52.
Watts RW, Watts JE, Seegmiller JE. Xanthine oxidase activity in human tissues and its inhibition by allopurinol (4-hydroxypyrazolo [3,4-d] pyrimidine). J Lab Clin Med. 1965;66(4):688-97.
